Zenflow is a South San Francisco medical device company that built the Spring, a small nitinol coil implanted through a flexible cystoscope to prop open the urethra and relieve the symptoms of an enlarged prostate (benign prostatic hyperplasia). Spun out of Stanford's Biodesign program in 2014, the company won FDA approval in December 2025 for a first-line interventional therapy that requires no catheter afterward, preserves sexual function, and can be reversed. It has raised roughly $85 million across multiple rounds and ran the multinational BREEZE pivotal trial to get there.
Adona Medical is a clinical-stage medical device company in Los Gatos, California developing the Delphi System, a chronically adjustable interatrial shunt with integrated bi-atrial pressure monitoring designed to personalize heart failure therapy over time. A Shifamed portfolio company founded in 2019 by Brian Fahey, Amr Salahieh, and Lewis Schwartz, Adona uses shape memory nitinol and an external induction catheter to resize the shunt after implantation without further invasive procedures.
Myra Vision is a Campbell, California medical device company developing the Calibreye Titratable Glaucoma Therapy Surgical System - a next-generation aqueous shunt with adjustable outflow channels that let surgeons fine-tune intraocular pressure in glaucoma patients non-invasively in the clinic, long after the implant goes in.
Maggie Nixon is the CEO of Capstan Medical, a Santa Cruz medtech startup building a robotic platform and catheter-delivered implants for minimally invasive mitral and tricuspid heart valve replacement. A nationally ranked high-school shot put and discus thrower, she earned a Stanford athletic scholarship, designed her own biomechanical engineering major, and then spent more than two decades at Intuitive Surgical across instrument design, clinical development, quality and regulatory, and China operations and strategy. In 2022 she reunited with her first Intuitive boss, Dan Wallace, to lead Capstan, where in 2025 her team completed the world's first robotic catheter mitral valve replacements in humans after raising a $110M Series C.